Evidence map›Paper›PMID 42611229›Full record

ArticleACS nano2026

Enhancing Human Skin Penetration with Biodegradable Enzymatic Nanomotors.

Carles Prado-Morales, Taco Waaijman, Inés Macías-Tarrío, Cristián Huck-Iriart, Tiziana Russo, Joël Gálvez-Savoca, Cesar Rodriguez-Emmenegger, Jasper J Koning, Samuel Sánchez

Abstract read
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carles Prado-MoralesInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.
Taco WaaijmanDepartment of Molecular Cell Biology and Immunology, Amsterdam UMC, Location VUMC, 1081 HVAmsterdam, The Netherlands.
Inés Macías-TarríoInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.
Cristián Huck-IriartALBA Synchrotron Light Source, Cerdanyola del Vallès, 08290Barcelona, Spain.ORCID 0000-0001-5734-2499
Tiziana RussoInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.ORCID 0009-0003-6943-1060
Joël Gálvez-SavocaInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.
Cesar Rodriguez-EmmeneggerInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.ORCID 0000-0003-0745-0840
Jasper J KoningDepartment of Molecular Cell Biology and Immunology, Amsterdam UMC, Location VUMC, 1081 HVAmsterdam, The Netherlands.
Samuel SánchezInstitute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST) , 08028Barcelona, Spain.ORCID 0000-0001-9713-9997

Funding

ALBA Synchrotron 2024098683ALBA Synchrotron 20250370417Departament d'Innovaci?, Universitats i Empresa, Generalitat de Catalunya 2021 SGR 01606European Regional Development Fund NAEuropean Social Fund Plus NAGeneralitat de Catalunya NAHorizon 2020 European Commission (EC) 101189426Horizon 2020 European Commission (EC) 866348Ministerio de Ciencia, Innovaci?n y Universidades CEX2023-001282 SMinisterio de Ciencia, Innovaci?n y Universidades PID2021-128417OB-I00Ministerio de Ciencia, Innovaci?n y Universidades PRE2022-102542Nederlandse Organisatie voor Wetenschappelijk Onderzoek 1292.19.019
6 · The paper itself

Abstract

The skin is the body's primary biological barrier, largely due to the highly organized structure of the stratum corneum (SC). Although essential for protection, this barrier function limits the efficacy of transdermal drug delivery, as most topically applied compounds fail to reach deeper skin layers at therapeutically relevant concentrations. Existing approaches often rely on physical disruption of the barrier, which can cause undesirable side effects. Moreover, many prior studies have been conducted in murine models, which do not accurately recapitulate human skin physiology, hindering the translation to humans. Here, we present an alternative approach using enzymatically powered nanomotors tested in a human reconstructed skin model. We developed organic nanomotors composed of poly(lactic-co-glycolic acid) functionalized with urease, and we proved their biocompatibility and degradability. Our results show that nanomotors penetrate the skin with 15.7% efficacy, 2.5 times more than passive nanoparticle controls. This enhanced penetration is attributed to their active motion and their ability to induce alterations in the lipid organization of the SC, an effect confirmed by synchrotron radiation small-angle X-ray scattering and electron microscopy. These findings highlight the potential of enzymatic nanomotors as a nondisruptive and effective platform for future transdermal delivery in human skin, combining advantages of both chemical enhancers and nanoparticles.

Indexed as

SkinSkin AbsorptionUreaseAdministration, CutaneousHumansLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerUreasebiological barrierhuman skin modelnanobotsnanomedicinenanomotorsskintransdermal delivery

Identifiers

PMID42611229
PMCPMC13492477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.